Advances in Hidradenitis Suppurativa

Multimedia Medical Education

Supported by an educational grant from AbbVie.*
Medical accuracy confirmed at release date.

Recent Advances in Our Understanding and Management of HS: From Mild to Worsening HS
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019
Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019
What Would You Do? Combined Medical and Surgical Approaches in Moderate-to-Severe HS
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019
Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019
What Would You Do? Troubling Cases of HS
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019
Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019
Ask the Faculty
from Choose Your Own HS Adventure: Going Beyond Current Guidelines
EADV 2019
Thrasyvoulos Tzellos, MD, MSc, PhD
Afsaneh Alavi, MD
Falk G. Bechara, MD
Release Date: 12 November 2019
Modifying the Impact of HS: Lifestyle Considerations
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018
Thrasyvoulos Tzellos, MD, MSc, PhD
Release Date: 15 October 2018
Addressing the Psychosocial Symptoms of HS
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018
Errol P. Prens, MD, PhD
Release Date: 15 October 2018
Easing the Pain: Approaches for Clinicians Managing HS
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018
Falk G. Bechara, MD
Release Date: 15 October 2018
What’s the Goal? Perspectives on What We Want to Achieve for Patients With HS
from Ticking All the Boxes: A Multidisciplinary Approach to Hidradenitis Suppurativa
EADV 2018
Errol P. Prens, MD, PhD
Release Date: 15 October 2018

Faculty Communications

Case Studies, Literature Reviews, and Survey Results

Highlights from the 6th EHSF Conference in 2017
Kelsey R. van Straalen, MD
Hessel H van der Zee, MD

Join the Discussion
Survey Report: How Do Clinicians Approach the Management of Hidradenitis Suppurativa?
Caitriona Ryan, MD

Join the Discussion
Literature Review: Evaluating the Psychological Burden of HS and Its Impact on Relationships and Sexual Function
Hessel H van der Zee, MD, PhD

Join the Discussion

Patient Case Studies

58-year-old male with severe psoriasis on Risankizumab presented with painful, left leg swelling with erythema and blisters...

71-year-old female with a history of psoriasis, 50 pack years smoking and recent Legionnaires disease who came to us complaining...

43 year-old man with HS who had used different treatments in 15 years. The patient showed improvement initially with adalimumab,...

See more >>

In the News

AAD Releases First-Ever Guidelines for Treating Paediatric Patients With Psoriasis
The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) have released guidelines to help ensure that paediatric psoriasis patients receive the best possible treatment and care. The joint AAD/NPF guidelines, published in the Journal of the American Academy of...
Psoriasis Appears Associated With Increased Risk of Developing, Dying of Cancer
Patients with psoriasis appear to have an increased risk of cancer incidence and cancer-related mortality, according to a study published in JAMA Dermatology. For the study, Alex Trafford, University of Manchester, Manchester, United Kingdom, and colleagues searched through 6 electronic databases...
Imaging Tests Help Reveal Heart Risks in Patients With Psoriatic Disease
Combining vascular imaging data with information on cardiovascular risk factors may improve the accuracy of cardiovascular risk stratification in patients with psoriatic disease, according to a study published in Arthritis...
See more >>

Conference Reports

Deucravacitinib Effective for Patients With Active Psoriatic Arthritis

By Louise Gagnon

OTTAWA, Ontario -- November 12, 2020 -- Deucravacitinib was effective, compared with placebo, over 16 weeks of treatment in patients with active psoriatic arthritis (PsA), according to a study presented at the 2020 Virtual Meeting of the American College of Rheumatology (...

Tildrakizumab Improves Joint, Skin Manifestations of Psoriatic Arthritis

By Denise Baez

NEW YORK -- November 5, 2020 -- Tildrakizumab improved joint and skin manifestations of psoriatic arthritis better than placebo through 52 weeks, and was well tolerated among patients, according to a study presented at the Virtual 29th Congress of the European Academy of...

Therapeutic Drug Monitoring Does Not Improve Remission Rates in Patients Starting Infliximab Therapy

By Eric Ramos

CHICAGO -- June 9, 2020 -- Therapeutic drug monitoring in patients with rheumatic diseases who are starting treatment with infliximab does not appear to be superior to standard treatment in order to achieve remission, according to a study presented at the 2020 Virtual...

see more >>

Recently Published

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1)
Atsuyuki Igarashi, Hidemi Nakagawa, Akimichi Morita, Yukari Okubo, Shigetoshi Sano, Shinichi Imafuku, Yayoi Tada, Masaru Honma, Alan M Mendelsohn, Masaki Kawamura, Mamitaro Ohtsuki
The effect of secukinumab treatment on inflammatory parameters in patients with psoriasis: A multicentre restrospective study
İsa An, Mustafa Aksoy, Erhan Ayhan, Murat Ozturk
Magnetic Resonance Imaging of Axial and Peripheral Disease in Psoriatic Arthritis: A Report From the 2020 GRAPPA Annual Meeting
Walter P Maksymowych, Mikkel Østergaard
See more >>

Full-Text Articles

Journal of Rheumatology
Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs
Gurjit S Kaeley, Lihi Eder, Sibel Zehra Aydin, Phoebe Rich, Catherine J Bakewell
Acta Dermato-Venereologica
Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study
Nikolai Dyrberg Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, Lars Erik Bryld, Christoffer V Nissen, Tomas Norman Dam, Kawa Khaled Ajgeiy, Lars Iversen, Lone Skov
Acta Dermato-Venereologica
Methotrexate Use for Patients with Psoriasis and Risk of Cutaneous Squamous Cell Carcinoma: A Nested Case-control Study
Filippos Giannopoulos, Martin Gillstedt, Marta Laskowski, Kasper Bruun Kristensen, Sam Polesie
See more >>

Hessel H van der Zee, MD, PhD and Caitriona Ryan, MD, invite you to explore the education and resources on this site, designed to provide a comprehensive approach to managing patients with hidradenitis suppurativa.

Hessel H van der Zee, MD, PhD
Erasmus University Medical Center
Rotterdam, the Netherlands

Caitriona Ryan, MD
St. Vincent's Hospital
Dublin, Ireland


User-friendly learning modules available in short and accessible formats.

Insights and developments in HS from leading experts.

Continuously updated news and conference coverage.

Helpful resources for your practice and patients.